about
Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data.Determinants of highly active antiretroviral therapy duration in HIV-1-infected children and adolescents in Madrid, Spain, from 1996 to 2012Complications of continuous renal replacement therapy in critically ill children: a prospective observational evaluation studyCan serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients?Nutritional status and clinical outcome of children on continuous renal replacement therapy: a prospective observational study.Predictors of attrition and immunological failure in HIV-1 patients on highly active antiretroviral therapy from different healthcare settings in Mozambique.Relationship between hyperglycemia, hormone disturbances, and clinical evolution in severely hyperglycemic post surgery critically ill children: an observational studyPediatric defibrillation after cardiac arrest: initial response and outcomeComparison of normal saline, hypertonic saline albumin and terlipressin plus hypertonic saline albumin in an infant animal model of hypovolemic shock.Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of OutcomePrediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography.Causes of death in pediatric patients vertically infected by the human immunodeficiency virus type 1 in Madrid, Spain, from 1982 to mid-2009.Impact of highly active antiretroviral therapy (HAART) on AIDS and death in a cohort of vertically HIV type 1-infected children: 1980-2006.Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.Infection in critically ill pediatric patients on continuous renal replacement therapy.Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.Antibodies to an epitope from the Cha human autoantigen are markers of Chagas' disease.IL7RA polymorphisms are not associated with AIDS progression.Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency.Toll-like receptor 8 (TLR8) polymorphisms are associated with non-progression of chronic hepatitis C in HIV/HCV coinfected patients.Prognostic Value of Transient Elastography in Human Immunodeficiency Virus-Infected Patients With Chronic Hepatitis C.Pediatric Extrapulmonary Tuberculosis: Clinical Spectrum, Risk Factors and Diagnostic Challenges in a Low Prevalence Region.Assessment of pain in critically ill children. Is cutaneous conductance a reliable tool?Circuit life span in critically ill children on continuous renal replacement treatment: a prospective observational evaluation study.SLC30A8 rs13266634 polymorphism is related to a favorable cardiometabolic lipid profile in HIV/hepatitis C virus-coinfected patients.Diagnostic accuracy of the APRI, FIB-4, and the Forns index for predicting liver fibrosis in HIV/HCV-coinfected patients: a validation study.Slow progression of human immunodeficiency virus and hepatitis C virus disease in a cohort of coinfected children.Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.Terlipressin versus adrenaline in an infant animal model of asphyxial cardiac arrest.Clinical course and mortality risk factors in critically ill children requiring continuous renal replacement therapy.Diagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: the HGM-3 index.Association of CD8+ T lymphocyte subsets with the most commonly used markers to monitor HIV type 1 infection in children treated with highly active antiretroviral therapy.Accuracy of three transcutaneous carbon dioxide monitors in critically ill children.An artificial neural network improves the non-invasive diagnosis of significant fibrosis in HIV/HCV coinfected patients.[Plasma antiretroviral levels in children with human immunodeficiency virus infection. Influence of sex and age].Measurement of cardiac output in children by bioreactance.Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers.Continuous renal replacement therapy in children after cardiac surgery.Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children.Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
P50
Q31139499-6C41130F-9554-4C7F-8D3C-8C3F668CAA83Q33553629-1B534412-C0DC-4C85-ACF3-E70492F6E935Q33612787-1FFD47C2-BFDA-433F-B559-F172E6230EB2Q33665359-AEAD0CD8-ADDC-4EAC-A7D3-4003CE000F8DQ34422967-9F4F601D-D814-4B62-9793-42101C5E91E9Q35077691-5B56CBDA-AB06-46A3-A09C-5D1E25470A8EQ35120617-D314F327-3F93-47CB-ABC2-3B7F8F74B55DQ35544660-0B5B7C6F-9DDF-4ECC-8CDF-1D419980A68AQ35582813-A00D6902-075B-40F0-A95C-54B7B3FED6ACQ35916020-8F8872B9-06A3-4D25-8D17-45CD3B8129C6Q38165157-B6EB52F8-58AF-4278-AF94-1F8A39F04FFFQ38440344-DCBA8FCA-6FCA-448A-9AFA-01571EE380D2Q38448015-29FDD6E4-59E5-4ADB-8BDB-26A83A709C36Q38472689-30F99F0A-9484-4248-96B7-4AF1F2B2D7F8Q38774319-936614CF-6A52-4AB7-B0CA-34C3AD37ACDCQ39008634-E503AE26-E68F-40EA-9C2F-789D396DC4B0Q39508836-D7F84C63-D3DA-4C6A-8749-236EFBB28BBEQ40087851-9E4DA127-529E-4C46-AB23-D96159B14FD3Q40103690-5C02A055-9B37-468D-983D-D2C2CF033F33Q40444355-FFB1E819-BE1F-4025-85B9-52CDE2E28370Q40456677-7A20BD92-C19B-4055-9059-F2B91BB738C3Q40535399-52F92192-8527-4772-AF67-1B43382AA9FBQ41250734-723AB74E-78F8-488C-97C8-788E993BFC00Q41839496-E7284E96-2FA1-4BFD-B0A0-CA17CB44C7CAQ42238889-25CD322E-B42A-4EF6-9246-DC9F9EE5E61BQ43039692-836C3ABD-58BE-45C8-ADF7-F94306A90BDEQ43040279-10FD62B3-0212-49A2-B325-DE8901642680Q43106603-D7EEAB9C-EC05-44F4-917C-DC0027F6F0B3Q43125684-8AEE9DE1-4C54-4B9C-9F2D-CE5B07ECB333Q43125691-66FBA4D8-E5D3-42A5-8F1D-624431F8F9AAQ43290742-26E5465E-0150-4699-A4D4-DE512F6C76A8Q43433369-844A2C25-FAD2-4D5F-81E2-B2B2DE7FD49EQ43537654-470EB0F0-AA48-4131-9920-B71D3B79917DQ43946257-E4784B39-B1E7-41FA-9AF3-589AAA6848EEQ43986399-370A88BB-B274-4C27-A4E5-06EC02C702ADQ44138896-4B5B3D60-3473-4C92-8EB1-E4F29A019D1BQ44272943-BC99276C-661D-4CEF-96BA-5F7274214E1DQ44604101-609D69F7-B63B-4DDD-9B39-BC10FA028DE2Q44838466-68765F43-D050-4475-BA45-6EEEB3F096A9Q45189088-FD5FB42E-52F3-4183-8473-0185832B0440
P50
description
researcher ORCID ID=0000-0002-8492-1565
@en
name
J M Bellón
@en
J M Bellón
@nl
type
label
J M Bellón
@en
J M Bellón
@nl
prefLabel
J M Bellón
@en
J M Bellón
@nl
P106
P31
P496
0000-0002-8492-1565